Novel Basal Insulin Formulations in the Modern Era of T2D Management

PK/PD Assessment of Insulin Analogs

Intrasubject Variability With NPH Insulin (As Measured by GIR)

Basal Insulins Are Not Equivalent

Insulin PD Affected by BMI

PD of Degludec U100 at Steady State*

PD of Glargine U100 With Different Doses

PD of Regular Human Insulin U500 and U100*

PD of Degludec U100 and U200*

PD of Glargine U100 vs U300*

What Does All This Mean?

Insulin Glargine U300

EDITION 2: Glargine U300 vs U100*

EDITION Pooled Analysis

Insulin Degludec

Degludec vs Glargine U100: Insulin-Naive Patients* at 1 Y

Degludec vs Glargine U100*: Basal-Bolus With Prandial Insulin Aspart

Degludec Variable Dosing† vs Glargine U100 or Degludec Dosed Regularly*

New Insulin Pens

New Data at ADA 2016

Discussion: Use of Basal Insulin Analogs in T2D

Discussion: Considerations for Selecting or Switching Basal Insulin Analogs

Discussion: Other Considerations

Concluding Remarks

Abbreviations